Recommended reading in population pharmacokinetic pharmacodynamics
暂无分享,去创建一个
[1] G. Molenberghs,et al. Linear Mixed Models for Longitudinal Data , 2001 .
[2] Stephen B. Duffull,et al. Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[3] Mats O. Karlsson,et al. Assumption Testing in Population Pharmacokinetic Models: Illustrated with an Analysis of Moxonidine Data from Congestive Heart Failure Patients , 1998, Journal of Pharmacokinetics and Biopharmaceutics.
[4] Marie Davidian,et al. Consequences of misspecifying assumptions in nonlinear mixed effects models , 2000 .
[5] Mats O. Karlsson,et al. Assessment of Actual Significance Levels for Covariate Effects in NONMEM , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[6] Lewis B. Sheiner,et al. Pharmacokinetic parameter estimates from several least squares procedures: Superiority of extended least squares , 1985, Journal of Pharmacokinetics and Biopharmaceutics.
[7] Peter I D Lee,et al. Design and Power of A Population Pharmacokinetic Study , 2004, Pharmaceutical Research.
[8] R B Smith,et al. An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug‐drug interaction , 1987, Clinical pharmacology and therapeutics.
[9] L B Sheiner,et al. Population pharmacokinetics/dynamics. , 1992, Annual review of pharmacology and toxicology.
[10] Geert Molenberghs,et al. Linear Mixed Models in Practice , 1997 .
[11] Stephen B. Duffull,et al. The use of simulated annealing for finding optimal population designs , 2002, Comput. Methods Programs Biomed..
[12] Lewis B. Sheiner,et al. A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation , 1996, Journal of Pharmacokinetics and Biopharmaceutics.
[13] R. Tibshirani,et al. Generalized Additive Models , 1991 .
[14] Lewis B. Sheiner,et al. Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[15] M. Gastonguay,et al. Population Pharmacokinetics of Ciprofloxacin in Pediatric Patients , 2003, Journal of clinical pharmacology.
[16] Lewis B. Sheiner,et al. Extended least squares nonlinear regression: A possible solution to the “choice of weights” problem in analysis of individual pharmacokinetic data , 1984, Journal of Pharmacokinetics and Biopharmaceutics.
[17] T H Grasela,et al. Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. , 1985, Developmental pharmacology and therapeutics.
[18] L B Sheiner,et al. Population Pharmacokinetics of Procainamide from Routine Clinical Data , 1984, Clinical pharmacokinetics.
[19] Peter L. Bonate,et al. The Effect of Collinearity on Parameter Estimates in Nonlinear Mixed Effect Models , 1999, Pharmaceutical Research.
[20] D. Stanski,et al. A three-step approach combining bayesian regression and NONMEM population analysis: Application to midazolam , 1991, Journal of Pharmacokinetics and Biopharmaceutics.
[21] Mats O. Karlsson,et al. Assessment of Type I Error Rates for the Statistical Sub-model in NONMEM , 2002, Journal of Pharmacokinetics and Pharmacodynamics.
[22] Lewis B. Sheiner,et al. Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.
[23] M. Rietschel,et al. Population pharmacokinetic analysis of mirtazapine , 2004, European Journal of Clinical Pharmacology.
[24] Marie Davidian,et al. Nonlinear Models for Repeated Measurement Data , 1995 .
[25] Nicholas H. G. Holford,et al. A Size Standard for Pharmacokinetics , 1996, Clinical pharmacokinetics.
[26] Geert Molenberghs,et al. Linear Mixed Models in Practice: A SAS-Oriented Approach , 1997 .
[27] M. O. Karlsson,et al. The importance of modeling interoccasion variability in population pharmacokinetic analyses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[28] D. Stram,et al. Variance components testing in the longitudinal mixed effects model. , 1994, Biometrics.
[29] K G Kowalski,et al. Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study. , 2001, Statistics in medicine.
[30] M. Karlsson,et al. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis , 2002, AAPS PharmSci.
[31] F. Follath,et al. Population pharmacokinetic parameters in patients treated with oral mexiletine , 2004, European Journal of Clinical Pharmacology.
[32] Lewis B. Sheiner,et al. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data , 1977, Journal of Pharmacokinetics and Biopharmaceutics.
[33] Nicholas H. G. Holford,et al. Population Pharmacokinetics and Pharmacodynamics: An Underutilized Resource , 1998 .
[34] Stuart L. Beal,et al. Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis , 1994, Journal of Pharmacokinetics and Biopharmaceutics.
[35] Didier Concordet,et al. Population pharmacokinetics/pharmacodynamics relationships of an anticancer drug. , 2003, Statistics in medicine.
[36] M. Rowland,et al. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies , 2004, European Journal of Clinical Pharmacology.
[37] Yong Ho Kim,et al. Model Appropriateness and Population Pharmacokinetic Modeling , 2003, Journal of clinical pharmacology.
[38] E. Antman,et al. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. , 2003, British journal of clinical pharmacology.
[39] J. Boissel,et al. Inter-study variability in population pharmacokinetic meta-analysis: when and how to estimate it? , 2000, Journal of pharmaceutical sciences.
[40] D. Bates,et al. Mixed-Effects Models in S and S-PLUS , 2001 .
[41] V. Carey,et al. Mixed-Effects Models in S and S-Plus , 2001 .
[42] Lewis B. Sheiner,et al. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: Routine clinical pharmacokinetic data , 1983, Journal of Pharmacokinetics and Biopharmaceutics.
[43] Lewis B. Sheiner,et al. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data , 1980, Journal of Pharmacokinetics and Biopharmaceutics.